aluates Reports

$ 0.0

Automative

CRISPR and CRISPR-Associated (Cas) Genes - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: March 2024

Report Code: QYRE-Auto-39I6706

China CRISPR and CRISPR Associated Cas Genes Market Report Forecast 2021 2027

BUY CHAPTERS

CRISPR and CRISPR-Associated (Cas) Genes - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-39I6706

Report

March 2024

Pages:130

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Thermo Fisher Scientific

Editas Medicine

Caribou Biosciences

CRISPR Therapeutics

Intellia Therapeutics Inc

CELLECTIS

Horizon Discovery Plc

Sigma-aldrich

Precision Biosciences

GenScript

Sangamo BioSciences, Inc.

Lonza Group Limited

Integrated DNA Technologies

New England Biolabs

Origene Technologies

CRISPR and CRISPR-Associated (Cas) Genes - Market Size

The global market for CRISPR and CRISPR-Associated (Cas) Genes was estimated to be worth US$ 1384.4 million in 2023 and is forecast to a readjusted size of US$ 9813.2 million by 2030 with a CAGR of 31.9% during the forecast period 2024-2030

CRISPR and CRISPR-Associated (Cas) Genes - Market

This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.

Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid.

The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.

Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.

By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.

Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics and Intellia therapeutics, Inc. are the top 5 players of CRISPR and CRISPR-Associated (Cas) Genes, with about 63% market shares.

CRISPR And CRISPR-Associated (Cas) Genes industry is relatively concentrated, manufacturers are mostly in the Europe and North America. Among them, North America region accounted for more than 45% of the total market of global CRISPR And CRISPR-Associated (Cas) Genes.

Report Scope

This report aims to provide a comprehensive presentation of the global market for CRISPR and CRISPR-Associated (Cas) Genes, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of CRISPR and CRISPR-Associated (Cas) Genes by region & country, by Type, and by Application.

The CRISPR and CRISPR-Associated (Cas) Genes market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CRISPR and CRISPR-Associated (Cas) Genes.

Market Segmentation

Scope of CRISPR and CRISPR-Associated (Cas) Genes - Market Report

Report Metric	Details
Report Name	CRISPR and CRISPR-Associated (Cas) Genes - Market
Forecasted market size in 2030	US$ 9813.2 million
CAGR	31.9%
Forecasted years	2024 - 2030
Segment by Type:	Genome Editing Genetic engineering gRNA Database/Gene Librar CRISPR Plasmid Human Stem Cells Genetically Modified Organisms/Crops Cell Line Engineering
Segment by Application	Biotechnology Companies Pharmaceutical Companies Academic Institutes Research and Development Institutes
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics, Inc., Cellectis, Horizon Discovery Plc, Sigma Aldrich, Precision Biosciences, Genscript, Sangamo Biosciences Inc., Lonza Group Limited, Integrated DNA Technologies, New England Biolabs, Origene Technologies
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CRISPR and CRISPR-Associated (Cas) Genes manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of CRISPR and CRISPR-Associated (Cas) Genes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of CRISPR and CRISPR-Associated (Cas) Genes in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the CRISPR and CRISPR-Associated (Cas) Genes - Market size in 2030?

Ans: The CRISPR and CRISPR-Associated (Cas) Genes - Market size in 2030 will be US$ 9813.2 million.

What is the CRISPR and CRISPR-Associated (Cas) Genes - Market share by region?

Ans: Among them, North America region accounted for more than 45% of the total market of global CRISPR And CRISPR-Associated (Cas) Genes.

Who are the main players in the CRISPR and CRISPR-Associated (Cas) Genes - Market report?

Ans: The main players in the CRISPR and CRISPR-Associated (Cas) Genes - Market are Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics, Inc., Cellectis, Horizon Discovery Plc, Sigma Aldrich, Precision Biosciences, Genscript, Sangamo Biosciences Inc., Lonza Group Limited, Integrated DNA Technologies, New England Biolabs, Origene Technologies

What are the Application segmentation covered in the CRISPR and CRISPR-Associated (Cas) Genes - Market report?

Ans: The Applications covered in the CRISPR and CRISPR-Associated (Cas) Genes - Market report are Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes

What are the Type segmentation covered in the CRISPR and CRISPR-Associated (Cas) Genes - Market report?

Ans: The Types covered in the CRISPR and CRISPR-Associated (Cas) Genes - Market report are Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering

1 Market Overview

1.1 CRISPR and CRISPR-Associated (Cas) Genes Product Introduction

1.2 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Forecast

1.3 CRISPR and CRISPR-Associated (Cas) Genes Market Trends & Drivers

1.3.1 CRISPR and CRISPR-Associated (Cas) Genes Industry Trends

1.3.2 CRISPR and CRISPR-Associated (Cas) Genes Market Drivers & Opportunity

1.3.3 CRISPR and CRISPR-Associated (Cas) Genes Market Challenges

1.3.4 CRISPR and CRISPR-Associated (Cas) Genes Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Players Revenue Ranking (2023)

2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Company (2019-2024)

2.3 Key Companies CRISPR and CRISPR-Associated (Cas) Genes Manufacturing Base Distribution and Headquarters

2.4 Key Companies CRISPR and CRISPR-Associated (Cas) Genes Product Offered

2.5 Key Companies Time to Begin Mass Production of CRISPR and CRISPR-Associated (Cas) Genes

2.6 CRISPR and CRISPR-Associated (Cas) Genes Market Competitive Analysis

2.6.1 CRISPR and CRISPR-Associated (Cas) Genes Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by CRISPR and CRISPR-Associated (Cas) Genes Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CRISPR and CRISPR-Associated (Cas) Genes as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Genome Editing

3.1.2 Genetic engineering

3.1.3 gRNA Database/Gene Librar

3.1.4 CRISPR Plasmid

3.1.5 Human Stem Cells

3.1.6 Genetically Modified Organisms/Crops

3.1.7 Cell Line Engineering

3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type

3.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value, by Type (2019-2030)

3.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Biotechnology Companies

4.1.2 Pharmaceutical Companies

4.1.3 Academic Institutes

4.1.4 Research and Development Institutes

4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application

4.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value, by Application (2019-2030)

4.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region

5.1.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2019-2024)

5.1.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2025-2030)

5.1.4 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value, 2019-2030

5.2.2 North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value, 2019-2030

5.3.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value, 2019-2030

5.4.2 Asia Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America CRISPR and CRISPR-Associated (Cas) Genes Sales Value, 2019-2030

5.5.2 South America CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value, 2019-2030

5.6.2 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions CRISPR and CRISPR-Associated (Cas) Genes Sales Value

6.3 United States

6.3.1 United States CRISPR and CRISPR-Associated (Cas) Genes Sales Value, 2019-2030

6.3.2 United States CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

6.3.3 United States CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value, 2019-2030

6.4.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China CRISPR and CRISPR-Associated (Cas) Genes Sales Value, 2019-2030

6.5.2 China CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

6.5.3 China CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan CRISPR and CRISPR-Associated (Cas) Genes Sales Value, 2019-2030

6.6.2 Japan CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea CRISPR and CRISPR-Associated (Cas) Genes Sales Value, 2019-2030

6.7.2 South Korea CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Sales Value, 2019-2030

6.8.2 Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India CRISPR and CRISPR-Associated (Cas) Genes Sales Value, 2019-2030

6.9.2 India CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

6.9.3 India CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Thermo Fisher Scientific

7.1.1 Thermo Fisher Scientific Profile

7.1.2 Thermo Fisher Scientific Main Business

7.1.3 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.1.4 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.1.5 Thermo Fisher Scientific Recent Developments

7.2 Editas Medicine

7.2.1 Editas Medicine Profile

7.2.2 Editas Medicine Main Business

7.2.3 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.2.4 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.2.5 Editas Medicine Recent Developments

7.3 Caribou Biosciences

7.3.1 Caribou Biosciences Profile

7.3.2 Caribou Biosciences Main Business

7.3.3 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.3.4 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.3.5 CRISPR therapeutics Recent Developments

7.4 CRISPR therapeutics

7.4.1 CRISPR therapeutics Profile

7.4.2 CRISPR therapeutics Main Business

7.4.3 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.4.4 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.4.5 CRISPR therapeutics Recent Developments

7.5 Intellia therapeutics, Inc.

7.5.1 Intellia therapeutics, Inc. Profile

7.5.2 Intellia therapeutics, Inc. Main Business

7.5.3 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.5.4 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.5.5 Intellia therapeutics, Inc. Recent Developments

7.6 Cellectis

7.6.1 Cellectis Profile

7.6.2 Cellectis Main Business

7.6.3 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.6.4 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.6.5 Cellectis Recent Developments

7.7 Horizon Discovery Plc

7.7.1 Horizon Discovery Plc Profile

7.7.2 Horizon Discovery Plc Main Business

7.7.3 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.7.4 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.7.5 Horizon Discovery Plc Recent Developments

7.8 Sigma Aldrich

7.8.1 Sigma Aldrich Profile

7.8.2 Sigma Aldrich Main Business

7.8.3 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.8.4 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.8.5 Sigma Aldrich Recent Developments

7.9 Precision Biosciences

7.9.1 Precision Biosciences Profile

7.9.2 Precision Biosciences Main Business

7.9.3 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.9.4 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.9.5 Precision Biosciences Recent Developments

7.10 Genscript

7.10.1 Genscript Profile

7.10.2 Genscript Main Business

7.10.3 Genscript CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.10.4 Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.10.5 Genscript Recent Developments

7.11 Sangamo Biosciences Inc.

7.11.1 Sangamo Biosciences Inc. Profile

7.11.2 Sangamo Biosciences Inc. Main Business

7.11.3 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.11.4 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.11.5 Sangamo Biosciences Inc. Recent Developments

7.12 Lonza Group Limited

7.12.1 Lonza Group Limited Profile

7.12.2 Lonza Group Limited Main Business

7.12.3 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.12.4 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.12.5 Lonza Group Limited Recent Developments

7.13 Integrated DNA Technologies

7.13.1 Integrated DNA Technologies Profile

7.13.2 Integrated DNA Technologies Main Business

7.13.3 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.13.4 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.13.5 Integrated DNA Technologies Recent Developments

7.14 New England Biolabs

7.14.1 New England Biolabs Profile

7.14.2 New England Biolabs Main Business

7.14.3 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.14.4 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.14.5 New England Biolabs Recent Developments

7.15 Origene Technologies

7.15.1 Origene Technologies Profile

7.15.2 Origene Technologies Main Business

7.15.3 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

7.15.4 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) & (2019-2024)

7.15.5 Origene Technologies Recent Developments

8 Industry Chain Analysis

8.1 CRISPR and CRISPR-Associated (Cas) Genes Industrial Chain

8.2 CRISPR and CRISPR-Associated (Cas) Genes Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 CRISPR and CRISPR-Associated (Cas) Genes Sales Model

8.5.2 Sales Channel

8.5.3 CRISPR and CRISPR-Associated (Cas) Genes Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Thermo Fisher Scientific

Editas Medicine

Caribou Biosciences

CRISPR Therapeutics

Intellia Therapeutics Inc

CELLECTIS

Horizon Discovery Plc

Sigma-aldrich

Precision Biosciences

GenScript

Sangamo BioSciences, Inc.

Lonza Group Limited

Integrated DNA Technologies

New England Biolabs

Origene Technologies

List of Tables

Table 1. CRISPR and CRISPR-Associated (Cas) Genes Market Trends

Table 2. CRISPR and CRISPR-Associated (Cas) Genes Market Drivers & Opportunity

Table 3. CRISPR and CRISPR-Associated (Cas) Genes Market Challenges

Table 4. CRISPR and CRISPR-Associated (Cas) Genes Market Restraints

Table 5. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Company (2019-2024)

Table 7. Key Companies CRISPR and CRISPR-Associated (Cas) Genes Manufacturing Base Distribution and Headquarters

Table 8. Key Companies CRISPR and CRISPR-Associated (Cas) Genes Product Type

Table 9. Key Companies Time to Begin Mass Production of CRISPR and CRISPR-Associated (Cas) Genes

Table 10. Global CRISPR and CRISPR-Associated (Cas) Genes Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CRISPR and CRISPR-Associated (Cas) Genes as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2019-2024) & (%)

Table 27. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions CRISPR and CRISPR-Associated (Cas) Genes Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions CRISPR and CRISPR-Associated (Cas) Genes Sales Value, (2025-2030) & (US$ Million)

Table 31. Thermo Fisher Scientific Basic Information List

Table 32. Thermo Fisher Scientific Description and Business Overview

Table 33. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 34. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of Thermo Fisher Scientific (2019-2024)

Table 35. Thermo Fisher Scientific Recent Developments

Table 36. Editas Medicine Basic Information List

Table 37. Editas Medicine Description and Business Overview

Table 38. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 39. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of Editas Medicine (2019-2024)

Table 40. Editas Medicine Recent Developments

Table 41. Caribou Biosciences Basic Information List

Table 42. Caribou Biosciences Description and Business Overview

Table 43. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 44. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of Caribou Biosciences (2019-2024)

Table 45. Caribou Biosciences Recent Developments

Table 46. CRISPR therapeutics Basic Information List

Table 47. CRISPR therapeutics Description and Business Overview

Table 48. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 49. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of CRISPR therapeutics (2019-2024)

Table 50. CRISPR therapeutics Recent Developments

Table 51. Intellia therapeutics, Inc. Basic Information List

Table 52. Intellia therapeutics, Inc. Description and Business Overview

Table 53. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 54. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of Intellia therapeutics, Inc. (2019-2024)

Table 55. Intellia therapeutics, Inc. Recent Developments

Table 56. Cellectis Basic Information List

Table 57. Cellectis Description and Business Overview

Table 58. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 59. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of Cellectis (2019-2024)

Table 60. Cellectis Recent Developments

Table 61. Horizon Discovery Plc Basic Information List

Table 62. Horizon Discovery Plc Description and Business Overview

Table 63. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 64. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of Horizon Discovery Plc (2019-2024)

Table 65. Horizon Discovery Plc Recent Developments

Table 66. Sigma Aldrich Basic Information List

Table 67. Sigma Aldrich Description and Business Overview

Table 68. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 69. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of Sigma Aldrich (2019-2024)

Table 70. Sigma Aldrich Recent Developments

Table 71. Precision Biosciences Basic Information List

Table 72. Precision Biosciences Description and Business Overview

Table 73. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 74. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of Precision Biosciences (2019-2024)

Table 75. Precision Biosciences Recent Developments

Table 76. Genscript Basic Information List

Table 77. Genscript Description and Business Overview

Table 78. Genscript CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 79. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of Genscript (2019-2024)

Table 80. Genscript Recent Developments

Table 81. Sangamo Biosciences Inc. Basic Information List

Table 82. Sangamo Biosciences Inc. Description and Business Overview

Table 83. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 84. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of Sangamo Biosciences Inc. (2019-2024)

Table 85. Sangamo Biosciences Inc. Recent Developments

Table 86. Lonza Group Limited Basic Information List

Table 87. Lonza Group Limited Description and Business Overview

Table 88. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 89. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of Lonza Group Limited (2019-2024)

Table 90. Lonza Group Limited Recent Developments

Table 91. Integrated DNA Technologies Basic Information List

Table 92. Integrated DNA Technologies Description and Business Overview

Table 93. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 94. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of Integrated DNA Technologies (2019-2024)

Table 95. Integrated DNA Technologies Recent Developments

Table 96. New England Biolabs Basic Information List

Table 97. New England Biolabs Description and Business Overview

Table 98. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 99. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of New England Biolabs (2019-2024)

Table 100. New England Biolabs Recent Developments

Table 101. Origene Technologies Basic Information List

Table 102. Origene Technologies Description and Business Overview

Table 103. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Products, Services and Solutions

Table 104. Revenue (US$ Million) in CRISPR and CRISPR-Associated (Cas) Genes Business of Origene Technologies (2019-2024)

Table 105. Origene Technologies Recent Developments

Table 106. Key Raw Materials Lists

Table 107. Raw Materials Key Suppliers Lists

Table 108. CRISPR and CRISPR-Associated (Cas) Genes Downstream Customers

Table 109. CRISPR and CRISPR-Associated (Cas) Genes Distributors List

Table 110. Research Programs/Design for This Report

Table 111. Key Data Information from Secondary Sources

Table 112. Key Data Information from Primary Sources

Table 113. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. CRISPR and CRISPR-Associated (Cas) Genes Product Picture

Figure 2. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)

Figure 4. CRISPR and CRISPR-Associated (Cas) Genes Report Years Considered

Figure 5. Global CRISPR and CRISPR-Associated (Cas) Genes Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by CRISPR and CRISPR-Associated (Cas) Genes Revenue in 2023

Figure 7. CRISPR and CRISPR-Associated (Cas) Genes Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Genome Editing Picture

Figure 9. Genetic engineering Picture

Figure 10. gRNA Database/Gene Librar Picture

Figure 11. CRISPR Plasmid Picture

Figure 12. Human Stem Cells Picture

Figure 13. Genetically Modified Organisms/Crops Picture

Figure 14. Cell Line Engineering Picture

Figure 15. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Market Share by Type, 2023 & 2030

Figure 17. Product Picture of Biotechnology Companies

Figure 18. Product Picture of Pharmaceutical Companies

Figure 19. Product Picture of Academic Institutes

Figure 20. Product Picture of Research and Development Institutes

Figure 21. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 22. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Market Share by Application, 2023 & 2030

Figure 23. North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)

Figure 24. North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (%), 2023 VS 2030

Figure 25. Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)

Figure 26. Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (%), 2023 VS 2030

Figure 27. Asia Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)

Figure 28. Asia Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (%), 2023 VS 2030

Figure 29. South America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)

Figure 30. South America CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (%), 2023 VS 2030

Figure 31. Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)

Figure 32. Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (%), 2023 VS 2030

Figure 33. Key Countries/Regions CRISPR and CRISPR-Associated (Cas) Genes Sales Value (%), (2019-2030)

Figure 34. United States CRISPR and CRISPR-Associated (Cas) Genes Sales Value, (2019-2030) & (US$ Million)

Figure 35. United States CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

Figure 36. United States CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (%), 2023 VS 2030

Figure 37. Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value, (2019-2030) & (US$ Million)

Figure 38. Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

Figure 39. Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (%), 2023 VS 2030

Figure 40. China CRISPR and CRISPR-Associated (Cas) Genes Sales Value, (2019-2030) & (US$ Million)

Figure 41. China CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

Figure 42. China CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (%), 2023 VS 2030

Figure 43. Japan CRISPR and CRISPR-Associated (Cas) Genes Sales Value, (2019-2030) & (US$ Million)

Figure 44. Japan CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

Figure 45. Japan CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (%), 2023 VS 2030

Figure 46. South Korea CRISPR and CRISPR-Associated (Cas) Genes Sales Value, (2019-2030) & (US$ Million)

Figure 47. South Korea CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

Figure 48. South Korea CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (%), 2023 VS 2030

Figure 49. Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Sales Value, (2019-2030) & (US$ Million)

Figure 50. Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

Figure 51. Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (%), 2023 VS 2030

Figure 52. India CRISPR and CRISPR-Associated (Cas) Genes Sales Value, (2019-2030) & (US$ Million)

Figure 53. India CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (%), 2023 VS 2030

Figure 54. India CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (%), 2023 VS 2030

Figure 55. CRISPR and CRISPR-Associated (Cas) Genes Industrial Chain

Figure 56. CRISPR and CRISPR-Associated (Cas) Genes Manufacturing Cost Structure

Figure 57. Channels of Distribution (Direct Sales, and Distribution)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions